IT'S ALL IN THE DETAILS 36 Osuga and co-workers report the results of a randomized, double-blind, placebo-controlled trial on 37 the effect of relugolix, 40 mg/day for 12 weeks, in women with pelvic pain associated with uterine 38 fibroids (1). Sixty-five women with a maximum numerical rating scale score of ≥4 during 1 39 menstrual cycle or other pain symptoms associated with uterine fibroids (e.g., lower abdominal or 40 low back pain) for ≥2 days during 1 menstrual cycle, were recruited. The primary endpoint was the 41 proportion of patients with a maximum score of ≤1 during the 28-day period before the final dose of 42 the study drug. Almost six women out of 10 achieved this outcome (57.6%) in the experimental 43 group versus almost none in the placebo group (3.1%). After 12 weeks of relugolix treatment the 44 median fibroid and uterine volume reduction was 37% and 42%, respectively. More women in the 45 relugolix group experienced untoward effects, especially hot flushes. 46
Pelvic pain, which is not the most frequent and clinically important symptom associated 47 with uterine fibroids, here had to occur specifically during menstruation. The rapid inhibition of 48 pituitary gonadotropins' release induced by relugolix, leads to anovulation, reduction of serum E2 49 to postmenopausal levels, amenorrhea and thus, by definition, relief of pain experienced during or 50 exacerbated by menstruations. As placebos generally do not induce amenorrhea, the results of this 51 trial were predictable. Moreover, it may not be excluded that some participants were suffering from 52 undetected endometriosis rather than allegedly symptomatic fibroids. 53
According to the authors, "blind maintenance was achieved by concealment of the 54 pharmacodynamics test results from all outside parties and personnel involved in the conduct of the 55 study until the randomization code was opened". However, the altered menstrual pattern and the 56 typical vasomotor symptoms associated with relugolix use, renders this measure insufficient to 57 ensure masking of treatment allocation. 58
The use of analgesics was restricted. Presumably, this favored the experimental group and it 59 would have been interesting to know what would have happened had analgesics be used without 60 restrictions. Only 5.4% of the women allocated to placebo used analgesics in the last month of the 61 Vercellini et al., 4 study. This is somewhat unexpected, considering that the main selection criterion was precisely 62 pain 63 64 ARE GnRH ANTAGONISTS SUPERIOR TO GnRH AGONISTS? 65
The present trial demonstrates that relugolix is effective in women with fibroids whose main 66 presenting symptom is pelvic pain. However, behind registration purposes, some authors question 67 the appropriateness of placebo-controlled studies when an effective treatment has already been 68 established (3,4), and women with symptomatic fibroids might be more interested in understanding 69 the added benefits of relugolix over the GnRH agonists they can currently use. 70
Relugolix was compared with leuprorelin in a non-inferiority trial conducted on patients 71 with fibroid-associated menorrhagia (4). Relugolix was associated with an earlier reduction in the 72 amount of uterine bleeding and a faster recovery of menses after drug discontinuation. All the other 73 outcomes were substantially similar in the two study groups, including the proportion of women 74 achieving amenorrhea, increase in hemoglobin levels, reduction in fibroid and uterine volume, 75 incidence and type of untoward effects, degree of bone mineral density loss, and improvements in 76
health-related quality of life. 77
Relugolix is clearly a novel drug from a pharmacologic viewpoint, but is the rapidity in the 78 onset and termination of action enough to define this and other GnRH antagonists really novel with 79 respect to GnRH agonists in terms of clinical effectiveness? A faster onset of action can be 80 beneficial in case of severe bleeding, and a faster termination of action is advantageous if 81 intolerable untoward effects arise. In other cases, such differences may result of limited importance. 82
Much emphasis is being put on avoidance of the flare-up phase when using GnRH 83 antagonists instead of agonists, but the practical impact of this few-day endocrine drawback on the 84 outcome of a treatment enduring months is difficult to quantify. Moreover, the initial pituitary 85 stimulation can be mitigated by injecting leuprorelin during the luteal phase. 86 Vercellini et al., 5 According to Mauri and D'Agostino a non-inferiority trial is justified when a new treatment 87 "promise greater safety or convenience, or less expense, while providing similar efficacy". (3) With 88 regard to convenience, i.e., once daily oral versus once monthly intramuscular use, individual 89 preferences seem predominant. Thus, in light of the similar efficacy and safety of GnRH agonists 90 and antagonists, the choice of relugolix would be justified by a lower cost compared with that of 91 leuprorelin. Indeed, a reduction in health care cost could determine the overall value of specific 92 medical interventions (5) . Will this be the case? 93 94 SHORT-TERM OR LONG-TERM THERAPY? 95
The mean participants' age in the two study groups was between 40 and 42 years. When 96 considering a medical therapy for symptomatic fibroids in women in their early forties, one crucial 97 issue is to comprehend if this will be a short-term preoperative measure or, alternatively, a long-98 term treatment aimed at avoiding surgery and reaching the physiologic menopause. 99
As the final common mechanism of action of GnRH antagonists and agonists is the same, 100
i.e., induced hypoestrogenism, relugolix exerts most likely only temporary effects on fibroid-101 associated symptoms and lesions' dimension. In this case, fibroid re-growth and symptoms' 102 reappearance are anticipated soon after drug discontinuation. Therefore, once the efficacy of 103 relugolix has been demonstrated in trials of a few-month duration, the obvious question that arises 104 is "what to do next"? 105
Trials on treatment of women with symptomatic fibroids with relugolix plus add-back 106 therapy for up to 2 years are ongoing. The definitive objective of this type of studies should be to 107 verify whether medical therapy could be considered a clinically effective and cost-effective 108 Vercellini et al., 6 Controlling indefinitely fibroid growth, menorrhagia, and pelvic pain by modulating ovarian 112 steroid production seems an attractive option for many women. However, clinical effectiveness and 113 cost-effectiveness of long-term GnRH antagonist therapy may vary considerably depending on 114 baseline patient conditions and duration of treatment. The balance may be tipped toward medical 115 therapy in patients at high surgical risk and in those who, presumably, are close to menopause. 116 However, in younger women the cost and the potential disadvantages of the medical choice increase 117 in parallel with the expected duration of treatment. 118
Hysterectomy for symptomatic fibroids is associated with a high degree of patient 119 satisfaction, and morbidity and social costs of surgery are reduced when the procedure is carried out 120 at laparoscopy or vaginally. In premenopausal women, ovarian sparing allows continuation of 121 gonadal function. Moreover, systematic opportunistic salpingectomy might substantially reduce the 122 risk of epithelial ovarian cancer. Incremental cost-effectiveness ratios (ICER) should be used to weigh trade-offs between 135 health outcomes and costs and identify those medical interventions that improve the health of 136 patients marginally and are not worth the additional costs required (5). This seems important not
